Interim Report 2 2019-10-01 - 2019-12-31
Opening remarks Financial During the second quarter of the fiscal year 2019/2020 the company raised KSEK 12,937 by issuing subscription warrants in line with the resolution adapted by the AGM 2018 and board meeting decision from February 2019. Clinical and scientific developments The company released further data from the ongoing clinical study in patients with early stage bladder cancer, also known as non-muscle-invasive bladder cancer (NMIBC). This patient group represents 70% of new bladder cancer diagnoses and affects 1.6 million patients in Europe. Current NMIBC treatments